The Diagnostic Value Non Invasive Tests in Predicting Liver Fibrosis

Document Type : Original Article


1 Research Institute for Infectious Diseases of Digestive System, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

2 Department of Paramedicine, Tehran University of Medical Sciences, Tehran, Iran.


Background and Objectives: Liver biopsy is the gold standard for assessing liver fibrosis.Scoring systems such as BARD and BAAT has been studied in the detection of liver fibrosis. The objective of this is study was to determine the diagnostic value of BARD and BAAT Scoring systems in predicting liver fibrosis.
Subjects and Methods: In this cross-sectional study, the study group was selected among patients whit breast cancer. Those with chronic liver disease were excluded from the study. Finally 60 female patients with breast cancer included and undergone liver elastography. Elastography results were compared with BARD and BAAT.
Results: The clinical data of the patients with liver stiffness degrees F0-F2 and F3-F4 based on transient elastography were compared. The rate of  BARD score 3-4 concordance with the F3-4  degrees of liver stiffness in transient elastography had a  sensitivity, specificity, positive and negative predictive value of 84.6 %, 72.3 %,45.8 %  and 94.4 % respectively with accuracy 75 % and odds ratio of 14.38 (95% CI: 2.8-73.9). The corresponding values for BAAT score were 91.5 % ,  93.6 % , 72.7 % and 89.8 % with an accuracy of 86.66 %  and odds ratio of 23.46  (95% CI:4.56 - 118 ).
Conclusions: In this study, there was a significant association between BAAT and BARD scores with advanced degrees of liver stiffness. In cases where liver elastography or liver biopsy is unavailability or patients are reluctant, the BAAT and BARD scores are useful for determining the severity of liver fibrosis.


1-Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 2008 May; 134(6): 1682-98.
2-Wong VWS, Vergniol J, Wong GLH, Foucher J, Chan HLY, Le Bail B, "et al". Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010 Feb; 51(2): 454-62.
3-Angulo P. Nonalcoholic fatty liver disease. New England Journal of Medicine. 2002 Apr; 346(16): 1221-31.
4-de Alwis NMW, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. Journal of hepatology 2008; 48(Sup 1): S104-S12.
5-Kotronen A, Yki-Järvinen H. Fatty liver a novel component of the metabolic syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 2008; 28(1): 27-38.
6-Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. Journal of Clinical Endocrinology & Metabolism 2008; 93(11 Sup 1): s74-s80.
7-Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008 Nov; 51(11): 1947-53.
8-Ong JP, Younossi ZM. Approach to the diagnosis and treatment of nonalcoholic fatty liver disease. Clinics in liver disease 2005 Nov; 9(4): 617-34.
9-Osono Y, Nakajima K, Hata Y. Hypertriglyceridemia and fatty liver: clinical diagnosis of fatty liver and lipoprotein profiles in hypertriglyceridemic patients with fatty liver. Journal of atherosclerosis and thrombosis 1995; 2(3 Sup 1): S47-52.
10-Targher G. Nonalcoholic Fatty Liver Disease and Atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology 2005; 25(7): e117-e8.
11-Wasmuth J, Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H. Hepatology, a clinical textbook. Portland: Flying; 2010.
12-Feldman M. Sleisenger and Fordtran's Gastrointestinal and liver disease: pathophysiology, diagnosis, management.9th ed. USA: Elsevior; 2010.Vol.1 P.956.
13-Loomba R. Should We Routinely Do Liver Biopsy in NAFLD Patients? aga perspectives. 2012 Jul; 8(3): 20.
14-Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008 Oct; 57(10): 1441-7.
15-Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, "et al". Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC gastroenterology 2006 Feb; 6(1): 1-13.
16-Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease. Hepatitis monthly 2011 Feb; 11(2): 103-6.
17-Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cardenas E, Sanchez-Avila F, Vargas-Vorackova F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 2008 Oct-Dec; 7(4): 350-7.
18-Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. Journal of hepatology  2009 Jun; 51(3): 433-45.
19-Talei A, Sadeghi-Hassanabadi A, Salabian J. A Preliminary Report on Breast Cancer Screening Program in Shiraz Southern Iran. Iran J Med Sc 1997; 22: 146-48.
20-Malekzadeh R, Poustchi H. Fibroscan for assessing liver fibrosis: An acceptable alternative for liver biopsy. Hepat Mon 2011 Mar; 11(3): 157-58.
21-Abenavoli L, Beaugrand M. Transient elastography in non-alcoholic fatty liver disease. Ann Hepatol 2012 Mar-Apr; 11(2): 172-8.
22-Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clinical gastroenterology and hepatology 2007 Oct; 5(10): 1214-20.
23-Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison's Prinicples of Internal Medicine. 18th ed. Newyork: McGraw Hill; 2012. Vol 2 P.
24-Raszeja-Wyszomirska J, Szymanik B, Ławniczak M, Kajor M, Chwist A, Milkiewicz P, "et al". Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC gastroenterology  2010; 10(1): 67.